Innogen, a Shanghai-based medical technology company, announced that its independently developed, human-derived, ...
Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...
Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.
NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...
Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results